Lucia Ricciardi1, Patrick Haggard2, Lieke de Boer3, Chiara Sorbera4, Max-Philipp Stenner5, Francesca Morgante4, Mark J Edwards6. 1. Institute of Molecular and Clinical Sciences, St George's University of London, London, United Kingdom. Electronic address: lucia.ricciardi2@gmail.com. 2. Institute of Cognitive Neuroscience, UCL, London, United Kingdom. 3. Institute of Cognitive Neuroscience, UCL, London, United Kingdom; Aging Research Center, Karolinska Institute, Stockholm, Sweden. 4. Department of Clinical and Experimental Medicine, University of Messina, Italy. 5. Department of Neurology, Otto-von-Guericke University Hospital Magdeburg, Germany. 6. Institute of Molecular and Clinical Sciences, St George's University of London, London, United Kingdom.
Abstract
BACKGROUND: Several aspects of volitional control of action may be relevant in the pathophysiology of impulsive-compulsive behaviours (ICB) in Parkinson's disease (PD). We aimed to explore multiple aspects of action control, assessing reward-related behaviour, inhibition (externally and internally triggered) and sense of agency in PD patients, with and without ICB compared to healthy subjects. METHODS: Nineteen PD patients with ICB (PD-ICB), 19 PD without ICB (PD-no-ICB) and 19 healthy controls (HC) underwent a battery of tests including: Intentional Binding task which measures sense of agency; Stop Signal Reaction Time (SSRT) measuring capacity for reactive inhibition; the Marble task, assessing intentional inhibition; Balloon Analog Risk Task for reward sensitivity. RESULTS: One-way ANOVA showed significant main effect of group for action binding (p = 0.004, F = 6.27). Post hoc analysis revealed that PD-ICB had significantly stronger action binding than HC (p = 0.004), and PD-no-ICB (p = 0.04). There was no difference between PD-no-ICB and HC. SSRT did not differ between PD groups, whereas a significant difference between PD-no-ICB and HC was detected (p = 0.01). No other differences were found among groups in the other tasks. CONCLUSIONS: PD patients with ICB have abnormal performance on a psychophysical task assessing sense of agency, which might be related to a deficit in action representation at cognitive/experiential level. Yet, they have no deficit on tasks evaluating externally and internally triggered inhibitory control, or in reward-based decision-making. We conclude that impaired sense of agency may be a factor contributing to ICB in PD patients.
BACKGROUND: Several aspects of volitional control of action may be relevant in the pathophysiology of impulsive-compulsive behaviours (ICB) in Parkinson's disease (PD). We aimed to explore multiple aspects of action control, assessing reward-related behaviour, inhibition (externally and internally triggered) and sense of agency in PDpatients, with and without ICB compared to healthy subjects. METHODS: Nineteen PDpatients with ICB (PD-ICB), 19 PD without ICB (PD-no-ICB) and 19 healthy controls (HC) underwent a battery of tests including: Intentional Binding task which measures sense of agency; Stop Signal Reaction Time (SSRT) measuring capacity for reactive inhibition; the Marble task, assessing intentional inhibition; Balloon Analog Risk Task for reward sensitivity. RESULTS: One-way ANOVA showed significant main effect of group for action binding (p = 0.004, F = 6.27). Post hoc analysis revealed that PD-ICB had significantly stronger action binding than HC (p = 0.004), and PD-no-ICB (p = 0.04). There was no difference between PD-no-ICB and HC. SSRT did not differ between PD groups, whereas a significant difference between PD-no-ICB and HC was detected (p = 0.01). No other differences were found among groups in the other tasks. CONCLUSIONS:PDpatients with ICB have abnormal performance on a psychophysical task assessing sense of agency, which might be related to a deficit in action representation at cognitive/experiential level. Yet, they have no deficit on tasks evaluating externally and internally triggered inhibitory control, or in reward-based decision-making. We conclude that impaired sense of agency may be a factor contributing to ICB in PDpatients.
Authors: Jared T Hinkle; Kate Perepezko; Liana S Rosenthal; Kelly A Mills; Alexander Pantelyat; Zoltan Mari; Laura Tochen; Jee Yun Bang; Medha Gudavalli; Nadine Yoritomo; Ankur Butala; Catherine C Bakker; Vanessa Johnson; Emile Moukheiber; Ted M Dawson; Gregory M Pontone Journal: Parkinsonism Relat Disord Date: 2017-11-21 Impact factor: 4.891
Authors: Yang Liu; Wery P M van den Wildenberg; Gorka Fraga González; Davide Rigoni; Marcel Brass; Reinout W Wiers; K Richard Ridderinkhof Journal: BMC Psychol Date: 2020-01-07
Authors: Alice Martini; Simon J Ellis; James A Grange; Stefano Tamburin; Denise Dal Lago; Greta Vianello; Nicola M J Edelstyn Journal: J Neural Transm (Vienna) Date: 2017-11-08 Impact factor: 3.575
Authors: Charlotte L Rae; Aysha Ahmad; Dennis E O Larsson; Marta Silva; Cassandra D Gould van Praag; Sarah N Garfinkel; Hugo D Critchley Journal: Sci Rep Date: 2020-03-06 Impact factor: 4.379